单词plasminogen-activator
网络: 纤溶酶原激活物；纤溶酶原激活剂；胞浆素原活化剂
Conclusion The diabetic nephropathy patients have imbalance of plasma plasminogen activator and its inhibitor system.
结论：糖尿病肾病患者存在血浆纤溶酶原激活物及其抑制物系统失衡。
abstract: Objective To investigate the plasminogen activator inhibitor changes in patients with diabetic nephropathy.
目的：探讨糖尿病肾病患者血浆纤溶酶原激活物抑制物的变化。
Recombinant tissue-type plasminogen activator (r-TPA) was also used when clinically indicated.
临床上有指征时也可应用重组组织型纤溶酶原激活剂。
Cost-effectiveness of recombinant tissue plasminogen activator in the management of acute ischemic stroke: a systematic review.
急性缺血性卒中患应用重组组织纤溶酶原激活剂治疗的效用成本：一项系统性回顾
The abnormal activity of tissue-type plasminogen activator(t-PA) is the most risk factor of prethrombotic state of cardiovascular diseases.
组织型纤溶酶原激活物（tPA）活性异常是心血管疾病血栓前状态的最危险因素。
abstract: Objective: To discuss the clinical value of detecting blood plasminogen activator and inhibitor in cancer patients.
目的：探讨恶性肿瘤患者血液纤溶酶原激活剂与抑制剂检测的临床应用价值。
THE EXPRESSION OF UROKINASE-TYPE PLASMINOGEN ACTIVATOR RECEPTOR IN ORAL SQUAMOUS CELL CARCINOMA.
尿激酶受体在口腔鳞癌中的表达。
A drug called tissue plasminogen activator -- tPA -- dissolves clots and restores blood flow.
而一种称为组织纤维蛋白溶酶原激活物（tPA）的药物可以溶解血块，并恢复血液流通。
The high-phenol group also experienced a greater drop in the activity of another clot promoter, plasminogen activator inhibitor-1.
高酚早餐组另一血栓促进因子——纤维蛋白溶酶原活化抑制因子-1的活性也呈现显著降低。
Plasminogen activator inhibitor-1(PAI-1)is the main regulator of the fibrinolytic system.
血浆纤溶酶原激活物抑制剂（PAI）-1是纤溶系统的主要调控因子。